Wave Life Sciences (WVE) AI Stock Analysis

• Market Cap: $1.28B
• Dividend Yield: N/A
• Average Volume (3M): 3.18M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.95
• Revenue Growth: 103.75%
• EPS Growth: 33.84%
• Country: US
• Employees: 287
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.32
• Shares Outstanding: 167,181,780
• 10 Day Avg. Volume: 2,276,778
• 30 Day Avg. Volume: 3,183,006
• PEG Ratio: -0.60
• Price to Book (P/B): 8.16
• Price to Sales (P/S): 15.79
• P/FCF Ratio: -11.26
• Enterprise Value/Market Cap: 0.83
• Enterprise Value/Revenue: 9.70
• Enterprise Value/Gross Profit: 10.10
• Enterprise Value/Ebitda: -8.49
• 1Y Price Target: $18.09
• Price Target Upside: 135.85% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 12
• EPS Forecast (FY): -1.19
• Revenue Forecast (FY): $41.65M

• Rating: 47 Neutral
• Price Target: $7.00 ▼(-8.74% Downside)

Wave Life Sciences' stock score is primarily impacted by its financial performance challenges, including negative profitability and cash flow issues. While the earnings call highlighted positive clinical advancements and a strong cash position, these are outweighed by the technical analysis indicating bearish momentum and the valuation concerns due to ongoing losses.

Positive Factors

Strong Cash Position

A strong cash position provides financial stability and flexibility, allowing Wave Life Sciences to invest in R&D and sustain operations without immediate external funding.

Clinical Advancements

Successful clinical advancements enhance the company's competitive position in RNA-targeted therapies, potentially leading to new market opportunities and revenue streams.

Revenue Growth

Improved revenue growth reflects increasing product adoption and market penetration, which can support long-term financial health and operational sustainability.

Negative Factors

Profitability Challenges

Persistent profitability issues can hinder the company's ability to reinvest in growth and may necessitate additional funding, impacting long-term financial stability.

Cash Flow Issues

Negative cash flows indicate liquidity challenges, limiting the company's ability to fund operations and growth initiatives without external financing.

Increased Expenses

Rising expenses, particularly in R&D, can strain financial resources and impact profitability, potentially delaying the company's path to sustainable growth.

Wave Life Sciences Business Overview & Revenue Model

Company Description

Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. It is developing oligonucleotides target ribonucleic acid to reduce the expression of disease-promoting proteins or restore the production of functional proteins, or modulate protein expression. The company also develops WVE-004, a C9orf72 molecule for the treatment of amyotrophic lateral sclerosis and frontotemporal dementia; WVE-003, a mutant huntingtin SNP3 molecule for the treatment of Huntington's disease; WVE-N531, an Exon 53 molecule for the treatment of Duchenne muscular dystrophy; and ATXN3, a discovery stage program for the treatment of spinocerebellar ataxia 3, as well as multiple preclinical programs for CNS disorders. In addition, it focuses on developing GalNAc-conjugated AIMers to treat hepatic indications comprising Alpha-1 antitrypsin deficiency (AATD); and two preclinical programs, such as Usher syndrome type 2A (USH2A) and retinitis pigmentosa due to a P23H mutation in the RHO gene (RhoP23H) for the treatment of retinal diseases. It has collaboration agreements with Pfizer Inc., Takeda Pharmaceutical Company Limited, University of Oxford, University of Massachusetts, Western Washington University, Grenoble Institute of Neurosciences, IRBM S.p.A, University of Louisville, and University College London. The company was incorporated in 2012 and is based in Singapore.

How the Company Makes Money

Wave Life Sciences generates revenue primarily through the development and commercialization of its therapeutic products. The company secures funding through partnerships with larger pharmaceutical companies, which may involve upfront payments, milestone payments upon achieving specific development goals, and royalties on future sales. Additionally, Wave may receive grants and funding from government and research institutions aimed at supporting innovative medical research. Significant collaborations with industry leaders can enhance its financial stability and provide access to resources necessary for advancing its product pipeline.

Wave Life Sciences Financial Statement Overview

Summary

Wave Life Sciences shows revenue growth but faces significant profitability and cash flow challenges. The negative net profit and EBIT margins, along with negative operating and free cash flows, highlight ongoing financial difficulties. The balance sheet indicates manageable debt but low equity ratio and negative return on equity, pointing to potential financial instability.

Income Statement

Wave Life Sciences shows a mixed performance in its income statement. The company has achieved a positive revenue growth rate of 16.27% in the TTM period, indicating an upward trajectory in sales. However, profitability remains a significant concern, with negative net profit and EBIT margins, reflecting ongoing operational challenges and high costs relative to revenue.

Balance Sheet

The balance sheet reveals a moderate debt-to-equity ratio of 0.16, suggesting manageable leverage. However, the return on equity is negative, indicating that the company is not generating profit from shareholders' equity. The equity ratio is also low, pointing to potential financial instability.

Cash Flow

Cash flow analysis highlights significant challenges, with negative operating and free cash flows. The free cash flow to net income ratio is slightly above 1, indicating that cash flow is closely aligned with net income, albeit both are negative. The company faces liquidity issues, as evidenced by the negative free cash flow growth rate.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	109.23M	108.30M	113.31M	3.65M	40.96M	20.08M
Gross Profit	104.87M	108.30M	113.31M	3.65M	40.96M	-110.87M
EBITDA	-124.70M	-101.74M	-58.79M	-152.61M	-117.18M	-145.26M
Net Income	-121.95M	-97.01M	-57.51M	-161.82M	-122.25M	-149.91M
Balance Sheet
Total Assets	241.38M	352.21M	274.95M	146.39M	207.01M	279.24M
Cash, Cash Equivalents and Short-Term Investments	196.22M	302.08M	200.35M	88.50M	150.56M	184.50M
Total Debt	19.77M	25.40M	32.12M	37.61M	29.92M	29.30M
Total Liabilities	116.83M	142.69M	235.32M	191.48M	174.51M	188.59M
Stockholders Equity	124.55M	209.51M	39.63M	-45.09M	32.50M	90.65M
Cash Flow
Free Cash Flow	-198.17M	-151.96M	-20.55M	-129.14M	-89.55M	-117.32M
Operating Cash Flow	-197.37M	-151.03M	-19.43M	-127.78M	-88.99M	-115.98M
Investing Cash Flow	-805.00K	-938.00K	-1.11M	-1.25M	-560.00K	-1.34M
Financing Cash Flow	83.52M	253.89M	132.53M	67.19M	55.83M	154.54M

Wave Life Sciences Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 7.67
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For WVE, the sentiment is Positive. The current price of 7.67 is above the 20-day moving average (MA) of 7.50, above the 50-day MA of 7.42, and below the 200-day MA of 7.86, indicating a neutral trend. The MACD of -0.10 indicates Negative momentum. The RSI at 53.98 is Neutral, neither overbought nor oversold. The STOCH value of 91.32 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for WVE.

Wave Life Sciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
STOK	60 Neutral	$1.78B	47.30	15.02%	―	1128.17%	―
PGEN	54 Neutral	$1.32B	―	-507.72%	―	59.20%	-155.65%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
WVE	47 Neutral	$1.28B	―	-86.51%	―	103.75%	33.84%
NUVB	45 Neutral	$2.75B	―	-52.49%	―	1137.19%	70.51%
RAPP	44 Neutral	$1.40B	―	-23.41%	―	―	―
ORIC	43 Neutral	$1.15B	―	-39.73%	―	―	4.29%

Wave Life Sciences Corporate Events

Wave Life Sciences Advances RNA Therapies Amid Financial Progress

Wave Life Sciences Pte. Ltd., a biotechnology company, is pioneering RNA medicines to address both rare and common disorders through its innovative PRISM platform. In its third-quarter 2025 earnings report, the company highlighted significant clinical advancements in its RNA-based treatments, particularly for obesity and alpha-1 antitrypsin deficiency (AATD). The company also reported a net loss of $53.9 million, an improvement from the previous year’s $61.8 million loss.

Wave Life Sciences’ Earnings Call Highlights Clinical and Financial Progress

Wave Life Sciences Ltd. recently held its third quarter 2025 earnings call, which exuded a strong positive sentiment. The company highlighted significant advancements in its clinical trials, particularly with WVE-007 and WVE-006, alongside financial improvements and a robust cash position. Despite increased expenses and a decrease in cash equivalents, the overall progress and optimistic outlook on future developments overshadowed these concerns.

Wave Life Sciences Reports Positive INLIGHT Trial Results

On October 29, 2025, Wave Life Sciences announced positive results from its INLIGHT clinical trial of WVE-007 for obesity, showing significant dose-dependent reductions in Activin E levels, which are linked to fat loss. The company also introduced WVE-008, a new RNA editing candidate for liver disease, and highlighted its advancements in RNA editing and silencing technologies, positioning itself as a leader in RNA medicines.

The most recent analyst rating on (WVE) stock is a Buy with a $18.00 price target. To see the full list of analyst forecasts on Wave Life Sciences stock, see the WVE Stock Forecast page.

Wave Life Sciences Advances in Duchenne Muscular Dystrophy Study with WVE-N531

Wave Life Sciences Pte. Ltd. is conducting an open-label Phase 1b/2 study titled ‘An Open-label Phase 1b/2 Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy.’ The study aims to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical effects of WVE-N531, an antisense oligonucleotide, in patients with Duchenne muscular dystrophy (DMD) who have a specific gene mutation amenable to exon 53 skipping intervention.

Wave Life Sciences’ New Study on WVE-N531: What Investors Need to Know

Wave Life Sciences Pte. Ltd. is conducting an open-label extension study titled ‘An Open-Label Extension Study to Investigate the Long-term Safety, Tolerability, Pharmacokinetics, and Efficacy of WVE-N531 in Patients With Duchenne Muscular Dystrophy Who Participated in Another Study of WVE-N531.’ The study aims to evaluate the long-term safety and effectiveness of the drug WVE-N531 in patients with Duchenne Muscular Dystrophy (DMD) who have previously participated in a related study.

Wave Life Sciences Advances WVE-006 Study for AATD Treatment

Study Overview: Wave Life Sciences Pte. Ltd. is conducting a Phase 1b/2a open-label study titled ‘A Phase 1b/2a Open-label Single Ascending Doses (SAD) and Multiple Ascending Doses (MAD) Research Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Participants With AATD Pi*ZZ on WVE-006 (RestorAATion-2).’ The study aims to evaluate the safety and effectiveness of WVE-006 in treating alpha-1 antitrypsin deficiency (AATD), a condition that can lead to lung and liver disease.

Wave Life Sciences’ WVE-007 Study: A New Frontier in Obesity Treatment

Wave Life Sciences Pte. Ltd. is conducting a Phase 1 clinical study titled ‘A Phase 1, Randomized, Double-blind, Placebo-controlled Study of Ascending Doses of WVE-007 to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Adults Living with Overweight or Obesity.’ The study aims to assess the safety and effectiveness of WVE-007, a new treatment for individuals with overweight or obesity, highlighting its potential significance in addressing a prevalent health issue.

Wave Life Sciences Highlights WVE-007 Obesity Treatment

On September 24, 2025, Wave Life Sciences updated its corporate presentation, highlighting advancements in its RNA medicines pipeline, particularly the development of WVE-007 for obesity treatment. The presentation emphasized the potential of WVE-007, a GalNAc-siRNA targeting INHBE, to offer a novel, long-acting, and muscle-sparing approach to obesity, addressing limitations of current treatments like GLP-1s. Preclinical data showed promising results in reducing body weight and visceral fat without muscle loss, suggesting significant implications for the company’s competitive positioning in the RNA therapeutics market.

The most recent analyst rating on (WVE) stock is a Buy with a $18.00 price target. To see the full list of analyst forecasts on Wave Life Sciences stock, see the WVE Stock Forecast page.

Wave Life Sciences Announces Positive Results for WVE-006 Study

On September 3, 2025, Wave Life Sciences announced positive results from its ongoing Phase 1b/2a RestorAATion-2 study of WVE-006, aimed at treating alpha-1 antitrypsin deficiency (AATD). The data demonstrated durable production of serum AAT protein at levels associated with reduced risk of liver and lung diseases, following repeat doses of WVE-006. The study showed that WVE-006 was well tolerated with a favorable safety profile, and the results support a monthly or less frequent dosing regimen. This development represents a significant milestone for RNA editing in treating AATD and highlights the potential of WVE-006 as a transformative treatment option.

The most recent analyst rating on (WVE) stock is a Buy with a $19.00 price target. To see the full list of analyst forecasts on Wave Life Sciences stock, see the WVE Stock Forecast page.